Clinical trial
Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With…
NCT00471484 · National Cancer Centre, Singapore, Other · Unknown status
Key facts
| NCT number | NCT00471484 |
|---|---|
| Title | Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery |
| Official title | A Phase II Trial of Oxaliplatin/Adriamycin/5 Fluorouracil in Continuous Infusion / Interferon α-2b (OXAFI) Combination as Neoadjuvant Therapy in Unresectable Non-Metastatic Hepatocellular Carcinoma |
| Lead sponsor | National Cancer Centre, Singapore, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Biological, Drug, Other, Procedure |
| Interventions | recombinant interferon alfa-2b, doxorubicin hydrochloride, fluorouracil, oxaliplatin, diagnostic laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method, adjuvant therapy, biopsy, neoadjuvant therapy and 1 more |
| Enrollment | 54 |
| Start date | Mar 1, 2007 |
| First posted | May 10, 2007 |
| Last update posted | Jun 22, 2011 |
| Countries | Singapore |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: